Cochrane Abstracts
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals: Cochrane systematic review
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tenofovir or Zidovudine in Three-drug Combination Therapy With One Nucleoside Reverse Transcriptase Inhibitor and One Non-nucleoside Reverse Transcriptase Inhibitor for Initial Treatment of HIV Infection in Antiretroviral-naïve Individuals: Cochrane Systematic Review." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three_drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non_nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral_naïve_individuals:_Cochrane_systematic_review.
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals: Cochrane systematic review. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three_drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non_nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral_naïve_individuals:_Cochrane_systematic_review. Accessed January 17, 2025.
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals: Cochrane systematic review. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three_drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non_nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral_naïve_individuals:_Cochrane_systematic_review
Tenofovir or Zidovudine in Three-drug Combination Therapy With One Nucleoside Reverse Transcriptase Inhibitor and One Non-nucleoside Reverse Transcriptase Inhibitor for Initial Treatment of HIV Infection in Antiretroviral-naïve Individuals: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 January 17]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three_drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non_nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral_naïve_individuals:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals: Cochrane systematic review
ID - 432835
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432835/all/Tenofovir_or_zidovudine_in_three_drug_combination_therapy_with_one_nucleoside_reverse_transcriptase_inhibitor_and_one_non_nucleoside_reverse_transcriptase_inhibitor_for_initial_treatment_of_HIV_infection_in_antiretroviral_naïve_individuals:_Cochrane_systematic_review
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
